{"groups":[{"description":"Participants were administered paclitaxel, 80 milligram per square meter (mg/m\\^2), intravenous (IV) infusion weekly (QW) for maximum of 36 weeks followed by dose-dense doxorubicin, 60 mg/m\\^2 or dose-dense epirubicin, 90 mg/m\\^2 IV (investigator's choice) plus cyclophosphamide, 600 mg/m\\^2, IV repeated every 2 weeks (Q2W) for a maximum of 20 weeks supported with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment.","id":"FG000","title":"Chemotherapy"},{"description":"Participants were administered atezolizumab 840 mg, IV infusion, Q2W in combination with chemotherapy (paclitaxel 80 mg/m\\^2, IV infusion QW for maximum of 22 weeks followed by dose-dense doxorubicin, 60 mg/m\\^2 or dose-dense epirubicin, 90 mg/m\\^2, IV (investigator's choice) plus cyclophosphamide, 600 mg/m\\^2, IV repeated Q2W for maximum of 17 weeks supported with G-CSF or GM-CSF treatment followed by atezolizumab, 1200 mg IV infusion every 3 weeks (Q3W) as a maintenance therapy to complete 1 year of atezolizumab treatment from the first dose.","id":"FG001","title":"Atezolizumab and Chemotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"88"},{"groupId":"FG001","numSubjects":"73"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"933"},{"groupId":"FG001","numSubjects":"927"}],"type":"Study Terminated By Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"26"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Disease Relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"72"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1098"},{"groupId":"FG001","numSubjects":"1101"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1084"},{"groupId":"FG001","numSubjects":"1093"}],"comment":"Safety Evaluable Population included all participants who received any amount of any study drug.","type":"Safety Evaluable Population"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1098"},{"groupId":"FG001","numSubjects":"1101"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 2199 participants were enrolled in the study. Participants were randomized in a 1:1 ratio to receive Atezolizumab and Chemotherapy or Chemotherapy alone.","recruitmentDetails":"Participants with newly diagnosed Stage II-III primary invasive Breast cancer (BC) that is of triple negative phenotype and who were to be treated with adjuvant systemic chemotherapy following definitive surgery, were enrolled in 342 centers in 31 countries."}